Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
2020 · The Lancet Oncology · 788 citations
https://doi.org/10.1016/s1470-2045(20)30453-8
G
Guillermo López-Vivanco
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
251
Papers
13.4K
Citations
34
h-index
66
i10-index
Guillermo López-Vivanco is an academic researcher from Hospital de Cruces. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies & Cancer Treatment and Pharmacology. The author has an h-index of 34, co-authored 214 publications.
ORCID: 0000-0003-3800-6224Papers by this author
worksOverall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Journal of Clinical Oncology · 327 citations
https://doi.org/10.1200/jco.21.02660
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
2013 · The Lancet Oncology · 221 citations
https://doi.org/10.1016/s1470-2045(13)70383-8
Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
2017 · Clinical & Translational Oncology · 51 citations
https://doi.org/10.1007/s12094-017-1684-4
Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
2012 · Molecular Cancer · 45 citations
https://doi.org/10.1186/1476-4598-11-25
Paclitaxel for progressive basal cell carcinoma
2006 · Journal of the American Academy of Dermatology · 18 citations
https://doi.org/10.1016/j.jaad.2005.07.036
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat